Group 1 - The company Shanghai Hollywave Electronic System Technology Co., Ltd. will hold a half-year performance briefing on September 3, 2025, from 11:00 to 12:00 [1][2] - The briefing will be conducted in an interactive online format via the Shanghai Stock Exchange Roadshow Center [2][3] - Investors can submit questions from August 27, 2025, to September 2, 2025, before 16:00, through the Roadshow Center website or via the company's email [2][3] Group 2 - Key participants in the briefing will include the company's Chairman and General Manager, Mr. Li Jilong, along with independent director Ms. Xu Xia, and CFO Mr. Zhang Xu [2] - After the briefing, investors can access the main content and details of the event through the Shanghai Stock Exchange Roadshow Center [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：688682 证券简称：霍莱沃 公告编号：2025-022 上海霍莱沃电子系统技术股份有限公司 关于召开 2025 年半年度业绩说明会的公告 会议召开时间：2025 年 9 月 3 日（星期三）11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 27 日（星期三）至 9 月 2 日（星期二）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@holly-wave.com 进行提问。公司将在说明会上对投资者普遍关注的问题于信 息披露允许的范围内进行回答。 上海霍莱沃电子系统技术股份有限公司（以下简称"公司"）将于 2025 年 8 月 28 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 ...

Summary of Key Points Core Viewpoint - The financing activities of Holaivo show a mixed trend with slight net selling observed in recent trading days, indicating potential investor caution [1] Financing Activities - On August 11, Holaivo had a financing buy amount of 0.11 billion, ranking 1284th in the two markets [1] - The financing repayment amount on the same day was 0.12 billion, resulting in a net sell of 67.91 thousand [1] - Over the last three trading days (August 7-11), Holaivo recorded financing buys of 0.11 billion, 0.16 billion, and 0.11 billion respectively [1] Securities Lending - On August 11, Holaivo had no shares sold short, with a net sell of 0.00 thousand shares [1]

Group 1 - The core viewpoint of the article highlights the financial performance and market activity of Holiwo (688682) as of August 11, 2025, with a closing price of 37.02 yuan, reflecting a 0.73% increase [1] - The company reported total operating revenue of 73.0981 million yuan for Q1 2025, representing a year-on-year growth of 23.26% [1] - The net profit attributable to shareholders reached 4.1418 million yuan, showing a significant year-on-year increase of 140.99% [1] - The company's non-recurring net profit was 2.1566 million yuan, with an impressive year-on-year growth of 776.42% [1] - Financial ratios indicate a current ratio of 3.636, a quick ratio of 2.948, and a debt-to-asset ratio of 24.91% [1] Group 2 - Holiwo has made investments in 7 companies and participated in 206 bidding projects, showcasing its active engagement in the market [2] - The company holds 52 trademark registrations and 22 patents, indicating a strong focus on intellectual property [2] - Additionally, Holiwo possesses 25 administrative licenses, further demonstrating its operational capabilities [2]

Group 1 - The core point of the article highlights the financing activities of the company 霍莱沃, which saw a financing buy-in amount of 0.20 billion yuan on August 6, ranking 869th in the market [1] - Over the last three trading days (August 4-6), 霍莱沃 received financing buy-ins of 0.11 billion yuan, 0.11 billion yuan, and 0.20 billion yuan respectively, indicating a consistent interest from investors [1] - On the same day, the company had a financing repayment amount of 0.15 billion yuan, resulting in a net buy of 4.74 million yuan [1] Group 2 - In terms of securities lending, the company had no shares sold or net sold on that day, indicating a stable position in this aspect [2]

本文源自：金融界 作者：智投君 8月5日，沪深两融数据显示，霍莱沃获融资买入额0.11亿元，居两市第1159位，当日融资偿还额0.11亿 元，净买入21.27万元。 最近三个交易日，1日-5日，霍莱沃分别获融资买入0.10亿元、0.11亿元、0.11亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 ...

Group 1 - The military industry sector continues to show strong performance, with companies like Steel Research High-Tech and New Yu Guo Ke rising over 10% [1] - Other companies in the sector, including Holley Wo, Hongdu Aviation, Changcheng Military Industry, Chenxi Aviation, and AVIC Shenyang Aircraft Corporation, also experienced gains [1] - According to Zheshang Securities, geopolitical conflicts are expected to persist into 2025, leading to practical testing of China's military trade export equipment in overseas conflicts, which may result in a revaluation of domestic defense and military enterprises [1]

Market Overview - The Shanghai Composite Index fluctuated around 3500 points, closing slightly down by 0.03% at 3503.78 points, while the Shenzhen Component Index and the ChiNext Index both fell by 0.22% to 10720.81 points and 2230.19 points respectively. The total trading volume in the Shanghai and Shenzhen markets was 146.19 billion yuan, a decrease of over 170 billion yuan from the previous day [1]. Human-Robot Concept - The human-robot concept saw significant activity, with stocks like Upwind New Materials hitting the daily limit, achieving a six-day consecutive rise. Other notable performers included Weichuang Electric, which rose approximately 14%, and Rongtai Co., Fuda Co., and Zhejiang Rongtai, all of which reached the daily limit [3][4]. - Industry experts indicate that the human-robot sector is at a "dawn" of industrialization, with mass production and large-scale application becoming feasible. The key to commercialization lies in reducing costs, which currently limit widespread adoption [6]. Innovative Drug Concept - The innovative drug sector experienced strong gains, with stocks such as Guangshengtang and Iwu Biotech rising around 16%. Other companies like Hasi Lian, Rundu Co., and Aosaikang also reached their daily limits. Notably, Lianhuan Pharmaceutical achieved six daily limit rises in the past eight trading days [8][9]. - Recent government initiatives, including the launch of the 11th batch of centralized drug procurement, focus on established drugs rather than new ones, which may benefit the innovative drug market. The introduction of measures to support high-quality development of innovative drugs is expected to enhance the role of commercial insurance in the healthcare system [10]. Pet Economy Concept - The pet economy concept gained traction, with stocks like Weike Technology rising over 10%, and companies such as Biological Shares and Lijuzhu Group hitting their daily limits. Other companies like Meinuohua and Yirui Biological also saw significant increases [12][13]. - Analysts suggest that the pet food sector remains a high-growth area, with domestic brands expected to continue their upward trajectory. Companies with overseas production capabilities, particularly in North America, are likely to benefit from favorable conditions despite existing tariff uncertainties [14].

Core Points - The company announced a profit distribution and capital increase plan, which includes a cash dividend of 0.2 yuan per share and a capital increase of 0.4 shares for every share held [2][4][5] - The total cash dividend to be distributed amounts to 14,548,413.60 yuan, and the total shares after the distribution will be 101,838,895 shares [4][11] - The plan was approved at the annual shareholders' meeting held on May 6, 2025 [2][3] Distribution and Capital Increase Plan - The profit distribution and capital increase plan is for the fiscal year 2024 [3] - The distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [3] - The cash dividend will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [4][6] Taxation Details - Individual shareholders holding shares for over one year will not be subject to personal income tax on the cash dividend, resulting in a net distribution of 0.2 yuan per share [7] - For shares held for one year or less, the company will not withhold tax at the time of distribution, but tax will be calculated upon transfer of the shares [7] - Qualified Foreign Institutional Investors (QFII) and Hong Kong investors will have a 10% withholding tax applied, resulting in a net cash dividend of 0.18 yuan per share [8][9] Share Capital Structure - The company confirmed that all strategic placement shares from its initial public offering have been fully listed and are in circulation [5][11] - After the implementation of the capital increase, the diluted earnings per share for the fiscal year 2024 will be 0.14 yuan [11]

证券代码：688682 证券简称：霍莱沃 公告编号：2025-021 上海霍莱沃电子系统技术股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.2元（含税） 每股转增0.4股 相关日期 | 股权登记日 | 除权（息）日 | 新增无限售条件流 | 现金红利发放日 | | --- | --- | --- | --- | | | | 通股份上市日 | | | 2025/6/4 | 2025/6/5 | 2025/6/5 | 2025/6/5 | 一、通过分配、转增股本方案的股东会届次和日期 本次利润分配及转增股本方案经公司2025 年 5 月 6 日的2024年年度股东会审 议通过。 二、分配、转增股本方案 1.发放年度：2024年年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公 司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： （2）转增股本的，由中国结算上海分公司根据股权登 ...